AXSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Axsome Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$155.81−1.33 (-0.85%)
Close on Oct 19, 2026
- Market cap
- $8.07B
- P/E (TTM)
- –
- Dividend yield
- –
Axsome Therapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product Sales | $216.36M | $189.40M | $194.70M | $169.78M | $148.96M | $120.36M | $117.33M | $103.74M | $86.52M | $74.10M | $70.75M | $57.13M | 99.1% | +45.2% |
| Royalty and Milestone Revenue | $2.02M | $1.80M | – | – | $1.08M | $1.11M | – | – | – | – | – | – | 0.9% | +86.5% |
| License Fee | – | – | – | – | – | – | – | – | – | – | $0 | $0 | – | – |
| Royalty [Member] | – | – | – | $1.21M | $1.08M | $1.11M | – | $1.03M | $646.00K | $903.00K | $783.00K | $667.00K | – | – |
By region
From the segment and revenue-disaggregation notes of Axsome Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.